NCT02941354 - Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 10, 2016

Primary Completion Date

June 20, 2017

Study Completion Date

June 20, 2017

Conditions

Congenital Bleeding DisorderHaemophilia A

Interventions

DRUG

turoctocog alfa

Each subject will receive a single dose of turoctocog alfa as an intravenous (i.v.) bolus injection of 50 IU/kg.

Trial Locations (15)

Novo Nordisk Investigational Site, Taipei

Novo Nordisk Investigational Site, Changhua

Novo Nordisk Investigational Site, Vienna

Novo Nordisk Investigational Site, Sofia

Novo Nordisk Investigational Site, Belgrade

Novo Nordisk Investigational Site, Richmond

Novo Nordisk Investigational Site, Madrid

Novo Nordisk Investigational Site, Málaga

Novo Nordisk Investigational Site, Hanover

Novo Nordisk Investigational Site, Vigo

Novo Nordisk Investigational Site, Memphis

Novo Nordisk Investigational Site, Valencia

Novo Nordisk Investigational Site, Bonn

Novo Nordisk Investigational Site, Chicago

Novo Nordisk Investigational Site, Peoria